← Back to Search

Time-Restricted Eating for Mild Cognitive Impairment

N/A
Recruiting
Led By Julie Pendergast, PhD
Research Sponsored by Julie Pendergast
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 45-95
Postmenopausal Women
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to study completion up to approximately 8 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will study how a time-restricted eating plan affects women with mild memory problems. It may help prevent Alzheimer's, which affects women twice as much as men.

Who is the study for?
This trial is for postmenopausal women aged between 45-95 who have been diagnosed with mild cognitive impairment. It aims to explore a dietary intervention that could potentially improve their condition.
What is being tested?
The study is testing the feasibility of time-restricted eating as an intervention to see if it can help manage or improve mild cognitive impairment in women.
What are the potential side effects?
Since this trial involves a dietary change rather than medication, side effects may include hunger, changes in energy levels, or potential impact on social and daily routines.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 45 and 95 years old.
Select...
I am a woman who has gone through menopause.
Select...
I have been diagnosed with mild memory or thinking problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment to study completion up to approximately 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to study completion up to approximately 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants adhering to TRE protocol

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Time-restricted eatingExperimental Treatment1 Intervention
Participants will have baseline and post-study data collected, including activity/sleep data, metabolic parameters (fasting labs and anthropometric measurements), and cognitive testing. In addition, food timing will be collected throughout the study. Subjects will be educated about the potential health benefits of time-restricted eating and will self-select a 10-hr window, during which all daily calories will be consumed for 8 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Time-restricted eating
2022
N/A
~850

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,443 Previous Clinical Trials
4,331,129 Total Patients Enrolled
Julie PendergastLead Sponsor
2 Previous Clinical Trials
231 Total Patients Enrolled
Julie Pendergast, PhDPrincipal InvestigatorUniversity of Kentucky

Media Library

Time-restricted eating Clinical Trial Eligibility Overview. Trial Name: NCT05858008 — N/A
Mild Cognitive Impairment Research Study Groups: Time-restricted eating
Mild Cognitive Impairment Clinical Trial 2023: Time-restricted eating Highlights & Side Effects. Trial Name: NCT05858008 — N/A
Time-restricted eating 2023 Treatment Timeline for Medical Study. Trial Name: NCT05858008 — N/A
~0 spots leftby Dec 2024